Skip to main content
Avvo Advisor

Stop searching and get answers.

Talk to an Avvo-vetted lawyer on the phone now. 15-min call for just $39.

Learn more

Client reviews

Not yet reviewed

About Me

Media Mentions: 

  • Quoted, “Patently vulnerable,” BioCentury, The Bernstein Report on BioBusiness, August 8, 2011

  • Quoted, “Myriad gene patent: recent court ruling to resonate with gene and stem patent holders, labs offering sequencing, experts say,” BioPharm Insight, August 8, 2011

  • Quoted, “Patent Community Sees Post-Myriad Issues’ Expects Either En Banc or High Court Review,” BNA’s Patent Trademark & Copyright Journal, August 5, 2011

  • Quoted, “Biotech Sizes up Federal Circuit Ruling in Myriad Case,” BioWorld Today, August 2, 2011

  • Quoted, “The Big Fight,”Genome Technology, July 2, 2011

  • Quoted, "Bay State Comes Out Ahead in Biotech Venture Funding," Boston Business Journal, October 8, 2010

  • Prominent Mention, "Changing Places," Mass High Tech, July 21, 2010

  • Featured Interview, "On The Cutting Edge of Biotech Law," The Metropolitan Corporate Counsel, June 2010

  • Featured Interview, "IP Law, Biotech and Business and Coping with Bilski and KSR," The Metropolitan Corporate Counsel, February 2009

  • Featured Interview, "Biotech Co. Counsel Moves Back to Proskauer," Law360, March 10, 2008

  • Quoted, "As Liability Grows, GCs Get Nervous," National Law Journal, September 25, 2006

  • Prominent Mention, "Codon Devices," Harvard Business School Case, June 5, 2006


Practice Areas


  1. Patent Infringement: 34%
  2. Life Sciences & Biotechnology: 33%
  3. Intellectual Property: 33%

Attorney Endorsements

5 total 

  • Jeremy P. Oczek

    Jennifer is an outstanding intellectual property lawyer with strong technical expertise in life sciences. She is especially skilled in offering practical, business-savvy advice. I highly endorse Jennifer.


    Jeremy Oczek Patent Infringement Attorney
    Relationship: Worked together on matter

  • Robert S. Blasi Jr.

    Jennifer is an exceptional attorney. She brings to bear a wealth of experience handling IP issues for life sciences companies. Her advice is refreshingly practical and constructive.


    Robert Blasi Licensing Attorney
    Relationship: Worked together on matter

Contact Info

Greenberg Traurig, LLP

One International Place
Boston, MA, 02110-2600



Professional Misconduct

We have not found any instances of professional misconduct for this lawyer.
Avvo Contributions
Legal Answers
Award NameGrantorDate Granted
2011 Tech LuminaryMass High Tech Business News and Boston Business Journal2011
Work Experience
TitleCompany NameDuration
ShareholderGreenberg Traurig LLP2010 - Present
PartnerProskauer Rose, LLP2008 - 2010
VP of IP, Chief Patent Counsel, GC and Corpoate SecretaryCodon Devices, Inc.2005 - 2008
AssociateProskauer Rose LLP2004 - 2005
AssociateTesta Hurwitz & Thibeault1997 - 2004
Association NamePosition NameDuration
MassChallenge, Inc. Annual Startup Competition and AcceleratorJudge and Mentor2010 - Present
The Center for Policy on Emerging TechnologiesBoard of Directors2009 - Present
Boston College Law School Business Advisory CouncilCouncil Member2008 - Present
Women Entrepreneurs in Science and TechnologyMember2008 - Present
American Intellectual Property Law AssociationMember2000 - Present
Boston Patent Law AssociationMember1997 - Present
Boston Bar AssociationMember1997 - Present
Publication NameTitleDate
Nature BiotechnologyBiotech Innovaton in a First-to-File World: You May Win the Race, but Can You Take Home the Prize?2012
BNA's Patent, Trademark & Copyright JournalHow to Get the Most From the PTO's Full First Action Interview Pilot Program2011
Intellectual Property & Technology Law JournalMyriad and the Patent-Eligibility of Genetic Inventions: What’s the Matter Under 35 U.S.C. § 101?2011
Prior Firm Client AlertImplication for Biotechnology Enterprises and Investors as District Court Invalidates Cancer Gene Patents2010
Prior Firm Client AlertIn re Bilski: Federal Circuit Affirms Patent Office in Narrowing Scope of Patentable Subject Matter2008
The Journal of BioLaw & BusinessTaking a Global View of a Life Sciences Company’s Patent Positio2004
Prior Firm Client AlertFederal Circuit Holds That in Determining Whether Infringement of a Patent Was Willful, Clients Can Now Assert Their Attorney-Client Privilege Without Risk of an Adverse Inference That a Legal Opinion Was Negative2004
Intellectual Property ObserverGene Patents: Testing the Limits2002
The Journal of BioLaw & BusinessE-Rights: Wagging the Electronic Tale2002
Intellectual Property ObserverNavigating the Complicated Terrain of Joint Ownership2001
Molecular Reproductive DevelopmentProduction of Live Offspring with Predicted Genotypes Using PCR-RFLP Analysis of Polar Bodies From Mouse Oocytes1995
Neuroscience LettersThe Effect of Ca2+ Channel Antagonists (Cadmium, ω-Conotoxin, GIVA, and Nitrendipine) on the Release of Angiotensin II from Fetal Rat Brain Cell Culture In Vitro1991
Neuroscience AbstractsThe Release of Angiotensin Following Isoproternol, Cholera Toxin, Forskolin and Phorbol Ester Stimulation of Fetal Rat Brain in Culture1990
Society for Neuroscience AbstractsThe Role and Potential Interaction of Adenylate Cyclase, Protein Kinase C, and Calmodulin on Angiotensin Release from Dissociated Brain Cell Cultures1990
School NameMajorDegreeGraduated
Boston College Law SchoolLawJD - Juris DoctorN/A
University of Illinois, Urbana-ChampaignCell and Structured BiologyBS - Bachelor of ScienceN/A
Speaking Engagements
Conference NameTitleDate
6th Tactical and Practical Guide to Freedom to OperateThe Master Class on Creating and Implementing an Iterative FTO Strategy: Utilizing FTO to Inform Product Development and Minimize IP Risks2012
16th Annual Advanced Forum on: Structuring, Analyzing and Negotiating Life Sciences Collaborative Agreements and AcquisitionsWhat the U.S. Patent Reform Act Means for Deal-Makers and Business Development Strategies2012
2011 National Biotechnology ConferenceIP and Data Exclusivity in the New Biosimilars Regulatory Framework2011
Legal and Regulatory IssuesThe Life Sciences Boom – Is Innovation and Transformation Enough to Maintain the Massachusetts Edge2008
Biotechnology Policy IssuesThe Future of Science and Technology, a Forum on the Presidential Election2008
Your Intellectual Property Team & StrategiesProfiting from Your IP2003